Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.
作者信息
Chen Mei-Ling, Sadrieh Nakissa, Yu Lawrence
机构信息
Center for Drug Evaluation and Research, Food and Drug Administration, 10903, New Hampshire Avenue, Silver Spring, Maryland, 20993-0002, USA,
出版信息
AAPS J. 2013 Oct;15(4):1043-50. doi: 10.1208/s12248-013-9509-z. Epub 2013 Jul 19.
Abstract
摘要
相似文献
1
Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs.
AAPS J. 2013 Oct;15(4):1043-50. doi: 10.1208/s12248-013-9509-z. Epub 2013 Jul 19.
2
Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence.
Eur J Pharm Sci. 2014 Dec 18;65:89-97. doi: 10.1016/j.ejps.2014.09.004. Epub 2014 Sep 16.
3
Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.
J Pharm Sci. 2014 Dec;103(12):3843-3858. doi: 10.1002/jps.24181. Epub 2014 Oct 13.
4
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fexofenadine.
J Pharm Sci. 2024 Sep;113(9):2981-2993. doi: 10.1016/j.xphs.2024.06.002. Epub 2024 Jun 8.
5
Biowaiver Monograph for Immediate-Release Dosage Forms: Levamisole Hydrochloride.
J Pharm Sci. 2023 Mar;112(3):634-639. doi: 10.1016/j.xphs.2022.12.014. Epub 2022 Dec 21.
6
BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
AAPS J. 2016 May;18(3):612-8. doi: 10.1208/s12248-016-9877-2. Epub 2016 Mar 4.
7
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate.
J Pharm Sci. 2017 Oct;106(10):2930-2945. doi: 10.1016/j.xphs.2017.04.068. Epub 2017 May 5.
8
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Clin Pharmacokinet. 2006;45(4):385-99. doi: 10.2165/00003088-200645040-00004.
9
Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron.
J Pharm Sci. 2019 Oct;108(10):3157-3168. doi: 10.1016/j.xphs.2019.05.033. Epub 2019 Jun 8.
10
The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.
Pharm Res. 2016 Jan;33(1):167-76. doi: 10.1007/s11095-015-1773-4. Epub 2015 Aug 19.
引用本文的文献
1
Osmotic laxatives do not alter dabigatran plasma concentration in healthy volunteers - a randomized, controlled, cross-over trial.
Front Pharmacol. 2025 May 12;16:1579014. doi: 10.3389/fphar.2025.1579014. eCollection 2025.
2
Mechanistic Modeling of In Vitro Biopharmaceutic Data for a Weak Acid Drug: A Pathway Towards Deriving Fundamental Parameters for Physiologically Based Biopharmaceutic Modeling.
AAPS J. 2024 Apr 4;26(3):44. doi: 10.1208/s12248-024-00912-y.
3
Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs.
Pharmaceutics. 2023 Sep 21;15(9):2366. doi: 10.3390/pharmaceutics15092366.
4
The Rat Continuous Intestine Model Predicts the Impact of Particle Size and Transporters on the Oral Absorption of Glyburide.
Mol Pharm. 2023 Jan 2;20(1):219-231. doi: 10.1021/acs.molpharmaceut.2c00597. Epub 2022 Dec 21.
5
Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
AAPS J. 2022 Jan 5;24(1):20. doi: 10.1208/s12248-021-00670-1.
6
Assessing CYP2C8-Mediated Pharmaceutical Excipient-Drug Interaction Potential: A Case Study of Tween 80 and Cremophor EL-35.
Pharmaceutics. 2021 Sep 17;13(9):1492. doi: 10.3390/pharmaceutics13091492.
7
Improved Hygroscopicity and Bioavailability of Solid Dispersion of Red Ginseng Extract with Silicon Dioxide.
Pharmaceutics. 2021 Jul 4;13(7):1022. doi: 10.3390/pharmaceutics13071022.
8
Digoxin absorption decreased independently of P-gp activity in rats with irinotecan-induced gastrointestinal damage.
J Pharm Health Care Sci. 2021 Jul 1;7(1):24. doi: 10.1186/s40780-021-00207-w.
9
Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.
J Clin Pharmacol. 2019 May;59(5):625-637. doi: 10.1002/jcph.1359. Epub 2018 Dec 18.
10
In Vitro and In Vivo Inhibition of Intestinal Glucose Transport by Guava (Psidium Guajava) Extracts.
Mol Nutr Food Res. 2018 Jun;62(11):e1701012. doi: 10.1002/mnfr.201701012. Epub 2018 May 17.
本文引用的文献
1
The effect of polyoxyethylene polymers on the transport of ranitidine in Caco-2 cell monolayers.
Int J Pharm. 2011 May 16;409(1-2):164-8. doi: 10.1016/j.ijpharm.2011.02.059. Epub 2011 Mar 4.
2
The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate.
Nat Rev Drug Discov. 2011 Jan;10(1):75; author reply 75. doi: 10.1038/nrd3028-c1.
3
The effects of excipients on transporter mediated absorption.
Int J Pharm. 2010 Jun 30;393(1-2):17-31. doi: 10.1016/j.ijpharm.2010.04.019. Epub 2010 Apr 24.
4
Membrane transporters in drug development.
Nat Rev Drug Discov. 2010 Mar;9(3):215-36. doi: 10.1038/nrd3028.
5
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond.
AAPS J. 2008 Jun;10(2):373-9. doi: 10.1208/s12248-008-9040-9. Epub 2008 Aug 5.
6
Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.
Pharm Res. 2008 Oct;25(10):2327-33. doi: 10.1007/s11095-008-9635-y. Epub 2008 Jul 4.
7
Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3).
AAPS J. 2008 Jun;10(2):300-5. doi: 10.1208/s12248-008-9030-y. Epub 2008 May 30.
8
Threshold for transitory diarrhea induced by ingestion of xylitol and lactitol in young male and female adults.
J Nutr Sci Vitaminol (Tokyo). 2007 Feb;53(1):13-20. doi: 10.3177/jnsv.53.13.
9
A modern view of excipient effects on bioequivalence: case study of sorbitol.
Pharm Res. 2007 Jan;24(1):73-80. doi: 10.1007/s11095-006-9120-4. Epub 2006 Oct 18.
10
In vitro - in vivo correlation: from theory to applications.
J Pharm Pharm Sci. 2006;9(2):169-89.
Zotero 插件